Company profile: ProFactor Pharma
1.1 - Company Overview
Company description
- Provider of recombinant blood factors for haemophilia, including a low-cost, GMP-optimized recombinant human Factor VIII (rhFVIII) for Haemophilia A. Offers a patent-protected cell line and production process delivering higher yields and lower costs, and collaborates with Bio Farma Persero on scale-up, clinical trials planned to commence in 2024, and commercialization.
Products and services
- Patent-protected cell-line and production process: A GMP-optimized, patent-protected rhFVIII cell line and manufacturing process architected to deliver low-cost production with higher yields for compliant, scalable coagulation factor supply
- Recombinant Human Factor VIII (rhFVIII): A recombinant coagulation protein engineered to treat Haemophilia A, produced via a low-cost process achieving higher yields and lower costs to broaden access to clotting therapy
- Collaboration with Bio Farma Persero: A scale-up-focused partnership structuring development, clinical trials, and commercialisation of rhFVIII, with clinical trials planned to commence in 2024 under the joint program
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProFactor Pharma
SyntnX
HQ: United States
Website
- Description: Provider of needle-free drug delivery solutions, discovering and developing novel, long-acting therapeutic products using proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. Technologies include the Transceptor drug delivery platform, harnessing the body's natural pathways.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SyntnX company profile →
Lung Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapies targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Pipeline includes LTI-03, a dual-mechanism dry powder inhaled treatment for idiopathic pulmonary fibrosis to improve lung function and reduce side effects, and LTI-01, a therapy for loculated pleural effusion that breaks down fibrous tissue to promote fluid drainage and alleviate symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lung Therapeutics company profile →
Clementia Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage, disease-modifying treatments for ultra-rare bone disorders and other debilitating diseases with high unmet medical need, including development of its lead product candidate, palovarotene, an oral small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clementia Pharmaceuticals company profile →
Inspiration Biopharmaceuticals
HQ: United States
Website
- Description: Provider of recombinant blood coagulation factor products for the treatment of hemophilia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inspiration Biopharmaceuticals company profile →
Soin Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical drug development focused on new medications for rare, orphan diseases, including a novel formulation of low-dose naltrexone to treat CRPS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Soin Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProFactor Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProFactor Pharma
2.2 - Growth funds investing in similar companies to ProFactor Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProFactor Pharma
4.2 - Public trading comparable groups for ProFactor Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →